UNH US S&P 500DJIARussell 1000 Earnings call · transcribed from the recording
UnitedHealth Group (UNH) · Q3 2026 results and valuation
Share price: $402.94 · 2026-11-11
Results Q3 2026 vs Q2 2026 · previous quarter · published 13 Oct 2026 and 16 Jul 2026
Net income down 25.1% on the previous quarter. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
−25.1%
Net income vs Q2 2026
Outlook given
Net income 4.11B vs 5.48B
Revenue +0.6%
Against the same quarter last year (Q3 2025) it is +75.0%, so the move on last quarter looks seasonal or timing-related rather than a trend.
2 · How management spoke
Typical
Less upbeat than 62% of company calls
Answers to analysts: upbeat, in line with the script.
Similar to last call.
3 · What stood out
Figure
UnitedHealth has expanded AI-enabled chart summarization to more than 40% of its employed clinicians, reducing chart review time by 33%.
Valuation
Is UnitedHealth Group undervalued?
Reverse DCF on net income from the last full fiscal year (no meaningful free cash flow: a bank, insurer or a year of negative cash flow) (2025-12-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
At 10.0% growth a year (3-year revenue growth), the model's fair value is $305.67 a share — the stock trades 32% above it. Today's price assumes 13.2% growth a year.
Current price
$402.94
close of 2026-11-11
Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.
+13.2% for 10 yrs
Fair value / share
$305.67
Buy below
$229.25
Price vs fair value
Overvalued 32%
Price vs buy-below price
Overvalued 76%
Read between the lines
-
Guidance
Based on its current outlook, UnitedHealth continues to view 2026 as a trough year for core Medicaid margins, which it now expects to be moderately better than negative 1%.
-
Guidance
AI-enabled information gathering and research have shortened appeal cycle times by 26%, improving both member and clinician experience, and UnitedHealth expects this to accelerate in 2027.
-
Last period
UnitedHealth's reported medical care ratio of 86.7% includes $860 million of net favorable prior period medical development, the majority of which is in-year development.
Source quote
“Our reported medical care ratio of 86.7% includes $860 million of net favorable prior period medical development, the majority of which is in-year development. Turning to medical costs. This compares to 89.4% in 2Q 2025.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q3 2026. Ring: Q2 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“As we previously noted, trends for commercial benefits are exceeding our initial expectations of 11%, driven by an acceleration of costs related to the No Surprises Act, greater cost intensity...”
“In Optum Insight, performance is benefiting from technology and AI-enabled improvements, including payment integrity and broader operating efficiency while we invest into the new areas to expand and modernize our...”
“Overall, Optum Health continued to deliver strong performance in the third quarter, driven by the continued return to value-based care principles, combined with strong execution across our clinical programs and...”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-09-30)
| Metric | Q3 2026period end 2026-09-30 | Q2 2026period end 2026-06-30 | Change | Q3 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 112.69B | 112.03B | +0.6% | 113.16B | −0.4% |
| Gross profit | 98.99B | 98.66B | +0.3% | 100.59B | −1.6% |
| Operating income | 6.56B | 7.99B | −17.9% | 4.32B | +52.1% |
| Net income | 4.11B | 5.48B | −25.1% | 2.35B | +75.0% |
| EPS | 4.56 | 6.04 | −24.5% | 2.59 | +76.1% |
| P/E today 22.5 | 21.0 | 26.7 | −5.7 | 18.0 | +3.0 |
Topics
Most discussed now
- New UnitedHealth is accelerating the modernization of its enterprise by advancing simplified and more responsive policies, processes, and…
- For this year's Medicare Advantage annual enrollment period, UnitedHealth is introducing AI-powered plan recommendation that use a member's…
- Costs remain stubbornly high across the entire healthcare landscape, and particularly in areas such as specialty pharmacy and acute…
- With adequate funding, UnitedHealth believes Medicare Advantage will continue to be the choice of American seniors, particularly those who…
- UnitedHealth continues to be respectful of continued elevated utilization trends, which typically step up in the back half of the...
Faded since Q2 2026
- Fading This resulted in another quarter of improved care management and greater operating discipline.
- Fading UnitedHealth's second quarter results and updated full year 2026 outlook demonstrate continuing progress toward delivering more consistent…
- Fading UnitedHealth expects the 2026 Medicare medical cost trend to come in below its initial estimate of around 10%.
- Fading On the clinical side, UnitedHealth is advancing approaches that better support care providers and drive measurable improvements to patient…
Latest announcements
Official filings, newest first.
- Results of operations · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K
- Shareholder vote results · SEC 8-K · routine
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Director or officer change · SEC 8-K